← Back to Search

Daily Adherence Reminders/Adherence Performance Feedback for Medication Adherence

N/A
Waitlist Available
Led By Chen Kenyon, MD
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up months 2, 4,7, 12
Awards & highlights

Study Summary

This study is evaluating whether financial incentives can help improve adherence to inhaled corticosteroids for children with asthma.

Eligible Conditions
  • Childhood Asthma
  • Medication Adherence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~months 2, 4,7, 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and months 2, 4,7, 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Monthly Adherence to Inhaled Corticosteroid Regimen (Unadjusted)
Secondary outcome measures
Adherence Trajectory
Changes in Child Asthma Control Tool (cACT) Score
Healthcare Costs of Utilization
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1: Incentives, plus reminders & feedback (IRF)Experimental Treatment2 Interventions
There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0). During the "Experiment" period (Months 1-3), Arm 1 will receive the IRF intervention. During the "Observation" period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF.
Group II: Arm 2: Reminders & feedback ONLYActive Control1 Intervention
There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0). During the "Experiment" period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives. During the "Observation" period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF.
Group III: Arm 3 (Control)Active Control1 Intervention
There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0). During the "Experiment" period (Months 1-3), Arm 3 will not receive any component of the IRF intervention. During the "Observation" period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF.

Find a Location

Who is running the clinical trial?

Children's Hospital of PhiladelphiaLead Sponsor
708 Previous Clinical Trials
8,580,934 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,698 Previous Clinical Trials
7,492,374 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,837 Previous Clinical Trials
47,851,502 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial
2019. "The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03907410.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top